OOIR: Observatory of International Research

Papers

(The H4-Index of Blood Advances is 55. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)

Article	Citations
Receiving CAR T-cells gets faster, but not for all in need	167
Amelioration of a von Willebrand disease type 2B phenotype in vivo upon treatment with allele-selective siRNAs	164
Mehta RS, Ramdial J, Kebriaei P, et al. Haploidentical vs HLA-matched sibling donor HCT with PTCy prophylaxis: HLA factors and donor age considerations. Blood Adv. 2024;8(20):5306-5314.	139
Smith CC, Levis MJ, Perl AE, et al. Molecular profile of FLT3-mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib. Blood Adv. 2022;6(7):2144-2155.	127
BCL11A-deficient human erythropoiesis is impaired in vitro and after xenotransplantation into mice	120
Abramson JS, Siddiqi T, Garcia J, et al. Cytokine release syndrome and neurological event costs in lisocabtagene maraleucel–treated patients in the TRANSCEND NHL 001 trial. Blood Adv. 2021;5(6)	120
MENIN MAINTENANCE THERAPY FOR ACUTE LEUKEMIA	112
Targeting the RBM39-MEK5 axis synergizes with bortezomib to inhibit the malignant growth of multiple myeloma	109
Transplant Outcomes Using Older Matched Sibling Donors Compared to Young Alternative Donors: A CIBMTR Analysis	104
Safety Run-In and Part 1 of GIMEMA AML1718: Venetoclax Combined with FLAI as Induction Treatment in Non-Low-Risk AML	103
Clinical Outcomes in Elderly Patients Treated Outside Clinical Studies: Highlighting the Octogenarian Experience	96
Interplay between iron metabolism, inflammation, and EPO-ERFE-Hepcidin axis in RDEB-associated chronic anemia	94
Asparaginase enzyme activity levels and toxicity in childhood acute lymphoblastic leukemia: a NOPHO ALL2008 study	90
Phase 1b trial of tagraxofusp in combination with azacitidine with or without venetoclax in acute myeloid leukemia	90
A novel 3D culture model recapitulates primary FL B-cell features and promotes their survival	87
Efficacy of checkpoint inhibition after CAR-T failure in aggressive B-cell lymphomas: outcomes from 15 US institutions	86
Impact of Vein-to-vein Time in Patients With R/R LBCL Treated With Axicabtagene Ciloleucel	85
Glucagon-Like Peptide 1 Receptor Agonists and Venous Thromboembolism in Type 2 Diabetes: A Target Trial Emulation	84
Factors associated with early quality of life response to palliative care during hematopoietic cell transplantation	84
Audit of B-cell Cancer Genes	84
A sweet deal: blocking NMDAR for safer t-PA in diabetes	83
Systemic Mastocytosis: Current Status and Challenges in 2024	83
Assessment of romiplostim immunogenicity in pediatric patients in clinical trials and in a global postmarketing registry	80
RNA-seq–based miRNA signature as an independent predictor of relapse in pediatric B-cell acute lymphoblastic leukemia	79
Reduced FVIII recovery associated with anti-FVIII PEG antibodies after BNT162b2 SARS-CoV-2 vaccination	77

Single-cell multiomics reveal divergent effects of DNMT3A- and TET2-mutant clonal hematopoiesis in inflammatory response	76
HMGA2 expression defines a subset of human AML with immature transcriptional signature and vulnerability to G2/M inhibition	76
Differential sialic acid content in adult and neonatal fibrinogen mediates differences in clot polymerization dynamics	76
Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia	74
Abnormalities of bone marrow B cells and plasma cells in primary immune thrombocytopenia	73
Single-cell dynamics of breakthrough toxicities following anakinra prophylaxis for axicabtagene ciloleucel in lymphoma	72
Persistent post-remission clonal hematopoiesis shapes the relapse trajectories of acute myeloid leukemia	71
Back from (BTKi) holiday	71
Mitigating T-Cell Mitochondrial Dysfunction in CLL to Augment CAR T-Cell Therapy: Evaluation in an Immunocompetent Model	71
Addressing and overcoming disparities in GVHD	70
Biomarker signatures in cancer patients with and without venous thromboembolism events: a substudy of CASSINI	70
Booster effect after SARS-CoV-2 vaccination in immunocompromised hematology patients with prior COVID-19	69
Real-world impact of emicizumab and immunosuppression on acquired hemophilia A: a multicenter US cohort	67
Optimized vitamin D repletion with oral thin film cholecalciferol in patients undergoing stem cell transplant	67
Cellular and humoral immune response to mRNA COVID-19 vaccination in subjects with chronic lymphocytic leukemia	66
Predictors of liver disease outcomes in individuals with hemophilia and HCV infection	64
The ASH-ASPHO Choosing Wisely Campaign: 5 hematologic tests and treatments to question	63
LSC17 score complements genetics and measurable residual disease in acute myeloid leukemia: an ALFA study	63
G6b-B regulates an essential step in megakaryocyte maturation	62
Autologous transplant and second malignancies in MM	61
Mass spectrometry vs immunofixation for treatment monitoring in multiple myeloma	60
Outcomes of patients with primary refractory multiple myeloma in the era of triplet and quadruplet induction therapy	59
Hard-wired biases in trials: maintenance azacitidine in patients with acute myeloid leukemia and framework for future trials	59
Framework of clonal mutations concurrent with WT1 mutations in adults with acute myeloid leukemia: Alliance for Clinical Trials in Oncology study	59
Risk profiling of patients with relapsed/refractory diffuse large B-cell lymphoma by measuring circulating tumor DNA	58
Development of iPSC-derived human bone marrow organoid for autonomous hematopoiesis and patient-derived HSPC engraftment	58
Conditioning intensity and probability of live birth after blood or marrow transplantation, a BMTSS report	57
Tyrosine kinase inhibitor for CML: all the same?	57
The fate of mitochondria during platelet activation	57
Single-cell immune profiling reveals a developmentally distinct CD4+ GM-CSF+ T-cell lineage that induces GI tract GVHD	56
Deletion of Y chromosome before allogeneic hematopoietic stem cell transplantation in male recipients with female donors	55
Enkurin: a novel marker for myeloproliferative neoplasms from platelet, megakaryocyte, and whole blood specimens	55
Post–hematopoietic stem cell transplantation immune-mediated anemia: a literature review and novel therapeutics	55